PharmaCyte Biotech, Inc. provided earnings guidance for Fiscal Year 2022. Net loss for fiscal year 2022 is expected to be approximately $4.2 million or approximately $0.27 per share, compared with a net loss of $3.6 million, or $2.45 per share, for the prior fiscal year.